Sumatriptan is a serotonin receptor agonist used to treat migraines and cluster headaches. Sumatriptan is the first of the triptans and was made available in Europe in 1991 to treat migraines.
- Mechanism
- Curator reviewed · 13 references
Sumatriptan is an agonist of 5-HT1B and 5-HT1D. This agonism leads to constriction of cranial blood vessels and inhibits the release of pro-inflammatory neuropeptides. Sumatriptan decreases carotid arterial blood flow, but increases blood flow velocity in the internal carotid artery and middle cerebral artery.[A179734 Agonism of the 5-HT1B and 5-HT1D receptors also inhibits sensory neurons, preventing the release of vasoactive peptides.[A179734 Sumatriptan does not cross the blood brain barrier.
- Primary indication
- A combination sumatriptan and naproxen tablet is indicated for the treatment of migraines with or without auras in patients 12 years of age and older.Curator reviewed · 5 structured indications
- Formula / weight
- C14H21N3O2S · 295.4 g/mol (avg)
- First approval
- Canada, 2001 · United States, 1993
- Code names
- GR 43175 A · GR 43175 C · GR 43175 X · NP-101 · SN 308
- Brand names
Resolves to
KQKPFRSPSRPDEB-UHFFFAOYSA-NSMILESCNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Sumatriptan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account